China's Regulatory Reforms Accelerate Biotech Innovation and Global Partnerships
China's regulatory reforms since 2015 have streamlined clinical trial and drug approval processes, accelerating development of advanced therapies like CAR-T and bispecific antibodies. These changes have boosted investor confidence and created opportunities for global pharmaceutical partnerships with Chinese biotech companies that have innovative pipelines but lack international marketing capabilities.
China's regulatory reforms are transforming the country's pharmaceutical sector from a generics manufacturing hub to an innovation powerhouse, creating opportunities for global partnerships. Starting in 2015 and continuing in 2020, China instituted reforms that streamlined clinical trial and approval processes, making them competitive with global standards and stimulating development of advanced therapies.
The 2015 "Opinions on the Reform of Review and Approval Process for Drugs and Medical Devices" and the 2020 revision of the "Provisions for Drug Registration" introduced expedited pathways for priority review, conditional approvals, and breakthrough therapy designations. These reforms shortened development timelines and reduced regulatory bottlenecks, particularly benefiting newer technologies like monoclonal and bispecific antibodies, and chimeric antigen receptor T-cell (CAR-T) approaches.
These regulatory changes have given investors increased confidence in China-developed therapies, helping companies attract and develop global partnerships. China's rapidly evolving biotech and pharma sector has achieved great success with therapeutics, though many companies lack the global marketing footprint needed to bring new drugs to patients worldwide. This combination creates opportunities for global and US/EU-based companies to partner with Chinese firms.
The reforms have stimulated development of drugs showing promise in treating previously intransigent diseases like pancreatic cancer. China is now home to a collection of biotech and pharmaceutical companies with portfolios of approved or late-stage therapies for treating life-threatening diseases.
Many therapeutics in late development or on the market come from advanced biotech categories, especially breakthrough therapies or expedited review. These include monoclonal and bispecific antibodies or other biologics treating cancer, metabolic disorders, or autoimmune disorders.
For example, Akeso's lung cancer bispecific antibody, Ivonescimab, outperformed Merck's Keytruda for non-small cell lung cancer (NSCLC), giving patients more than 11 months without progression compared to Keytruda's 5.8 months. Sinopharm Group's Anlotinib is already approved for nine cancer indications, with three more under review. Innovent Biologics has both a GLP-1 compound (mazdutide) already approved, as well as its foothold in oncology with sintillmab.
The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) recently published two guidelines related to CAR-T therapies, providing clearer direction for regulatory handling of such therapies. The release of these CAR-T guidelines implies completion of the overall regulatory policy direction for cell therapies in the country.
For research originating in China, oncology and metabolic diseases are a near-term sweet spot, including anti-cancer monoclonal and bispecific antibodies, and synthetic hormones (including GLP-1s) for metabolic diseases. AI-born pipelines and non-traditional drug discovery are growing in China, with companies like Insilico Medicine. Global companies should anticipate rapid expansion beyond China through China-global partnerships.